Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver

Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients

(2010) A. H. Diacon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects

(2009) A. M. Ginsberg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Assessment of the Effects of the Nitroimidazo-Oxazine PA-824 on Renal Function in Healthy Subjects

(2009) A. M. Ginsberg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Crystal Structures of F420-dependent Glucose-6-phosphate Dehydrogenase FGD1 Involved in the Activation of the Anti-tuberculosis Drug Candidate PA-824 Reveal the Basis of Coenzyme and Substrate Binding

(2008) Ghader Bashiri et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

(2008) Andrew M. Thompson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution

(2008) Robert F. Anderson et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release

(2008) R. Singh et al.   SCIENCE

A new Gateway® vector and expression protocol for fast and efficient recombinant protein expression in Mycobacterium smegmatis

(2007) Rachael M. Goldstone et al.   PROTEIN EXPRESSION AND PURIFICATION